ALK and non-small cell lung carcinoma: This large retrospective study included 377 patients with EGFR/ALK wild-type, metastatic nonsquamous NSCLC treated with first-line pembrolizumab-combination therapy whom we were able to follow for a median of 31 months until data cutoff at the end of August 2020.